Astellas
PharmaTokyo, Japan, Japan · Est. 2005 · 20,000 employees
Astellas Pharma is a Japanese pharmaceutical company focused on innovative treatments in oncology, immunology, and other therapeutic areas through research and development.
13
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
28
Indications↗
Distinct diseases across all programs
939
Clinical Trials↗
All sponsored trials (all statuses)
46
Orange Book Patents
Across 8 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
13 drugs in development
Approved2
Phase 31
Phase 23
Phase 18
Preclinical5
By Therapeutic Area
top 6
Oncology
838%
Ophthalmology
314%
Immunology
210%
Dermatology
15%
Psychiatry
15%
Infectious Disease
15%
R&D Momentum
75/100
Pipeline Velocity
49/100
Trial Completion Rate
91/100
Pipeline Concentration
21/100
Pipeline Freshness
69/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Recruiting
A Phase 1b/2 Study of ASP388B as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors
Sep 19, 2026
Active, not recruiting
A Study to Evaluate Seroprevalence of Antibodies to AAV8 and Assessment of Biomarkers in Patients With Late-Onset Pompe Disease
Sep 18, 2026
Recruiting
A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
Sep 17, 2026
Active, not recruiting
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Sep 17, 2026
Recruiting
A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants With Macular Dystrophies With a Stargardt-type Clinical Presentation
Sep 16, 2026
Recruiting
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
Sep 15, 2026
Terminated
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Sep 15, 2026
Terminated
A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect and Biomarker Response of ASP5502 in Healthy Adults and Participants With Primary Sjögren's Syndrome
Sep 12, 2026
Active, not recruiting
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Sep 12, 2026
Recruiting
A Phase 1, Multicenter, Open-Label, Ascending-Dose and Phase 2, Randomized, Double-Masked, Sham-Controlled, Clinical Study to Evaluate the Safety and Efficacy of ASP2767 in Participants With Optic Neuropathy Due to Glaucoma
Sep 12, 2026
Recruiting
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Sep 12, 2026
Recruiting
A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 Plus Chemotherapy (CAPOX or mFOLFOX6) With Pembrolizumab vs Placebo Plus Chemotherapy With or Without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive
Details
Company Info
Company Overview
$55.0B
Mkt Cap
$13.2B
Revenue
—
Cash
CEOKenji Yasukawa
Founded2005
Employees20,000
HQTokyo, Japan, Japan
Websiteastellas.com
LinkedInCompany Page
Therapeutic Focus
oncologyimmunologyurologygastroenterology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
1
—
—
—
—
Cardiovascular(1 drug)
Dermatology(1 drug)
1
—
—
—
1
Dermatology(1 drug)
Immunology(2 drugs)
1
1
—
—
1
Immunology(2 drugs)
Infectious Disease(1 drug)
—
—
—
—
1
Infectious Disease(1 drug)
Nephrology(1 drug)
—
—
—
—
1
Nephrology(1 drug)
Oncology(8 drugs)
1
5
3
1
—
Oncology(8 drugs)
Ophthalmology(3 drugs)
—
2
—
—
1
Ophthalmology(3 drugs)
Psychiatry(1 drug)
—
—
—
—
1
Psychiatry(1 drug)
Unknown / Other(3 drugs)
3
—
—
—
1
Unknown / Other(3 drugs)
Regulatory
Regulatory Timeline
20121 event
FDAAug 31
Xtandi — XTANDI
Application NDA203415 (NDA)
20143 events
FDASep 19
Lexiscan — LEXISCAN
Application NDA022161
FDAMar 29
Lexiscan — LEXISCAN
Application NDA022161
FDAJan 9
Lexiscan — LEXISCAN
Application NDA022161
20151 event
FDAMar 6
Cresemba — CRESEMBA
Application NDA207501 (NDA)
20171 event
FDAJan 17
Lexiscan — LEXISCAN
Application NDA022161
20182 events
FDANov 28
Xospata — XOSPATA
Application NDA211349 (NDA)
FDAMay 31
Lexiscan — LEXISCAN
Application NDA022161
20202 events
FDAAug 4
Xtandi — XTANDI
Application NDA213674 (NDA)
FDAMay 26
VESIcare — VESICARE LS
Application NDA209529 (NDA)
20211 event
FDAMar 25
Myrbetriq — MYRBETRIQ GRANULES
Application NDA213801 (NDA)
20221 event
FDANov 22
Cresemba — CRESEMBA
Application NDA207500 (NDA)
20233 events
FDAAug 4
Izervay — IZERVAY
Application NDA217225 (NDA)
FDAMay 12
Veozah — VEOZAH
Application NDA216578 (NDA)
FDAMay 12
Veozah — VEOZAH
Application NDA216578
20244 events
FDADec 16
Veozah — VEOZAH
Application NDA216578
FDAOct 18
VYLOY — VYLOY
Application BLA761365
FDAOct 18
VYLOY — VYLOY
Application BLA761365 (BLA)
FDAAug 31
Veozah — VEOZAH
Application NDA216578
20251 event
FDAJun 6
VYLOY — VYLOY
Application BLA761365
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)